Which is the original drug manufacturer of dasatinib? What is the difference between the original version of this drug and the generic version?

Dasatinib (Dasatinib) is a targeted therapy drug that is a tyrosine kinase inhibitor (TKI). It is mainly used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It blocks the proliferation and growth of leukemia cells by inhibiting the tyrosine kinase activity of the BCR-ABL fusion protein. This drug was originally developed and produced by **Pfizer (Pfizer) **. It is the original drug of dasatinib, and the original version produced by Pfizer is also common on the market.

Original drug manufacturer——Pfizer Pharmaceuticals

Pfizer (Pfizer) is a leading global pharmaceutical company headquartered in the United States. The original drug dasatinib developed and produced by it has been widely used since its launch. Pfizer's original drug dasatinib is approved for the treatment of multiple leukemia types such as chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Pfizer's original drugs have been verified through many years of clinical trials and have a quality control system that has undergone strict standards and supervision. Therefore, they are widely regarded as one of the first-choice drugs for the treatment of leukemia.

The difference between original drugs and generic drugs

1.Ingredients and active ingredients: The biggest difference between original drugs and generic drugs is the manufacturer. An originator drug is a drug developed by the original research and development company (such as Pfizer) and received market approval for the first time. Generic drugs are drugs produced by other companies based on the formula and active ingredients of the original drug after the patent of the original drug expires. The main active ingredients of generic drugs are the same as those of the original drugs, and the pharmacological effects and therapeutic effects should also be the same.

2.Drug quality and consistency: Original drugs usually undergo strict quality control standards during their production process, and every link from raw material procurement, production process, inspection and testing to packaging and transportation is strictly supervised. Large pharmaceutical companies such as Pfizer generally ensure the high quality, consistency and stability of their drugs, ensuring that every tablet meets international pharmaceutical standards. Although generic drugs must meet the quality standards of drug regulatory agencies, there may sometimes be minor differences in quality control due to possible differences in production processes and technologies. Although these differences generally do not affect efficacy, some patients may have allergic reactions or intolerances to certain excipients or dosage forms of specific generic drugs.

3.Price difference:Original drugs are usually more expensive due to factors such as research and development costs, clinical trial expenses, and patent protection periods. The original drug Dasatinib produced by Pfizer may be relatively expensive on the market, especially if there is no medical insurance or insurance coverage. In comparison, the price of generic drugs is usually cheaper because generic drug manufacturers do not need to bear the costs of development, clinical trials, etc. and can produce drugs at a lower cost, thereby providing more competitive prices. For some financially disadvantaged patients, generic drugs offer a more affordable option.

4.Clinical verification and patent protection: The original drug has been verified through long-term clinical research, and all efficacy and safety data have been certified by authoritative organizations, so it has more clinical evidence support. Pfizer's dasatinib has passed rigorous clinical trials and is widely used around the world. Although generic drugs are produced according to the formula of the original drug, they usually need to provide certain data to prove their consistency with the original drug in terms of efficacy and safety before going on the market. Although generic drugs can be marketed without re-conducting complete clinical trials, they must demonstrate no significant differences in pharmacokinetics, pharmacodynamics, etc. from the brand-name drugs.

5.Regulation and approval procedures: The production and sales of original drugs require a long process of research and development, clinical trials, and approval by drug regulatory agencies (such asFDA, EMA, etc.). The entire process is long and complex. Since generic drugs already have clinical data support for the original drugs, the approval process is usually faster. Generic drug companies are required to submit data on the consistency of the ingredients, efficacy and safety of their products with the original drugs to the drug regulatory agency, and then obtain marketing approval.

The original drug of Dasatinib (Dasatinib) is produced by Pfizer Pharmaceuticals. As a targeted therapy drug, it has been widely used to treat chronic myelogenous leukemia and acute lymphoblastic leukemia. Although original drugs and generic drugs are identical in terms of ingredients and therapeutic effects, there are differences in price, production quality control, and approval procedures between original drugs and generic drugs. For patients, the decision to use a brand-name drug or a generic drug should take into account the drug's quality, price, availability, and doctor's advice. On the premise of ensuring therapeutic effect, generic drugs provide a more economical option for patients with limited financial conditions.

Reference materials:https://go.drugbank.com/drugs/DB01254